News Avacta hoping to disrupt antibody drug dominance Avacta is one of several biotechs turning their backs on mabs.
News Three's a crowd as Tecentriq approved in lung cancer Cancer immunotherapy approved in second line.
News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
News Clovis takes stock as rival Tesaro shines Oncology firm could make acquisition if ovarian cancer drug approved.
Partner Content Partner Content The next step in the fight against cancer: Making CAR-T a vi... Four years ago, Emily Whitehead, who was just seven years old at the time, inadvertently became headline news as her previously incurable acute lymphoblastic leukaemia (ALL) moved into remission an
News Gamida Cell's cell therapy treatment gains breakthrough stat... Regulator to expedite review of blood cancer treatment
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
